Vir Biotechnology Financials
| VIR Stock | USD 6.95 0.02 0.29% |
Vir |
Vir Biotechnology Stock Summary
Vir Biotechnology competes with CureVac NV, Krystal Biotech, Propanc Biopharma, Blueprint Medicines, and Amylyx Pharmaceuticals. Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Vir Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 444 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US92764N1028 |
| CUSIP | 92764N102 |
| Location | California; U.S.A |
| Business Address | 1800 Owens Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.vir.bio |
| Phone | 415 906 4324 |
| Currency | USD - US Dollar |
Vir Biotechnology Key Financial Ratios
Vir Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Vir Biotechnology's current stock value. Our valuation model uses many indicators to compare Vir Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vir Biotechnology competition to find correlations between indicators driving Vir Biotechnology's intrinsic value. More Info.Vir Biotechnology is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Vir Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Vir Biotechnology Systematic Risk
Vir Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vir Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Vir Biotechnology correlated with the market. If Beta is less than 0 Vir Biotechnology generally moves in the opposite direction as compared to the market. If Vir Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vir Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vir Biotechnology is generally in the same direction as the market. If Beta > 1 Vir Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Vir Biotechnology is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Vir has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Vir Biotechnology's financials are consistent with your investment objective using the following steps:- Review Vir Biotechnology's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Vir Biotechnology's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Vir Biotechnology's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Vir Biotechnology's stock is overvalued or undervalued.
Vir Biotechnology March 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Vir Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vir Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vir Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Vir Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vir Biotechnology's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.59 | |||
| Information Ratio | 0.0246 | |||
| Maximum Drawdown | 71.23 | |||
| Value At Risk | (5.60) | |||
| Potential Upside | 5.16 |
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.